TY - JOUR AU - Cattaneo, R. AU - Russell, S. J. PY - 2017 DA - 2017// TI - How to develop viruses into anticancer weapons JO - PLoS Pathog VL - 13 UR - https://doi.org/10.1371/journal.ppat.1006190 DO - 10.1371/journal.ppat.1006190 ID - Cattaneo2017 ER - TY - JOUR AU - Martin-Liberal, J. AU - Ochoa de Olza, M. AU - Hierro, C. AU - Gros, A. AU - Rodon, J. AU - Tabernero, J. PY - 2017 DA - 2017// TI - The expanding role of immunotherapy JO - Cancer Treat Rev VL - 54 UR - https://doi.org/10.1016/j.ctrv.2017.01.008 DO - 10.1016/j.ctrv.2017.01.008 ID - Martin-Liberal2017 ER - TY - JOUR AU - Russell, S. J. AU - Peng, K. W. AU - Bell, J. C. PY - 2012 DA - 2012// TI - Oncolytic virotherapy JO - Nat Biotechnol VL - 30 UR - https://doi.org/10.1038/nbt.2287 DO - 10.1038/nbt.2287 ID - Russell2012 ER - TY - JOUR AU - Seymour, L. W. AU - Fisher, K. D. PY - 2016 DA - 2016// TI - Oncolytic viruses: finally delivering JO - Br J Cancer VL - 114 UR - https://doi.org/10.1038/bjc.2015.481 DO - 10.1038/bjc.2015.481 ID - Seymour2016 ER - TY - JOUR AU - Lichty, B. D. AU - Breitbach, C. J. AU - Stojdl, D. F. AU - Bell, J. C. PY - 2014 DA - 2014// TI - Going viral with cancer immunotherapy JO - Nat Rev Cancer VL - 14 UR - https://doi.org/10.1038/nrc3770 DO - 10.1038/nrc3770 ID - Lichty2014 ER - TY - STD TI - Russell SJ, Peng KW. Oncolytic Virotherapy: a contest between apples and oranges. Mol Ther. 2017. ID - ref6 ER - TY - STD TI - Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2016;3(6):841–9. ID - ref7 ER - TY - JOUR AU - Ferguson, M. S. AU - Lemoine, N. R. AU - Wang, Y. PY - 2012 DA - 2012// TI - Systemic delivery of oncolytic viruses: hopes and hurdles JO - Adv Virol VL - 2012 UR - https://doi.org/10.1155/2012/805629 DO - 10.1155/2012/805629 ID - Ferguson2012 ER - TY - STD TI - European Medicines Agency: Imlygic EPAR Product Information. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002771/WC500201079.pdf. Accessed 27 July 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002771/WC500201079.pdf ID - ref9 ER - TY - STD TI - Food and Drug Administration: US prescribing information. IMLYGIC (talimogene laherparepvec). 2015. http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM469575.pdf. Accessed 27 Jul 2017. UR - http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM469575.pdf ID - ref10 ER - TY - JOUR AU - Puzanov, I. AU - Milhem, M. M. AU - Minor, D. AU - Hamid, O. AU - Li, A. AU - Chen, L. AU - Chastain, M. AU - Gorski, K. S. AU - Anderson, A. AU - Chou, J. PY - 2016 DA - 2016// TI - Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.67.1529 DO - 10.1200/JCO.2016.67.1529 ID - Puzanov2016 ER - TY - JOUR AU - Kuhn, I. AU - Harden, P. AU - Bauzon, M. AU - Chartier, C. AU - Nye, J. AU - Thorne, S. AU - Reid, T. AU - Ni, S. AU - Lieber, A. AU - Fisher, K. PY - 2008 DA - 2008// TI - Directed evolution generates a novel oncolytic virus for the treatment of colon cancer JO - PLoS One VL - 3 UR - https://doi.org/10.1371/journal.pone.0002409 DO - 10.1371/journal.pone.0002409 ID - Kuhn2008 ER - TY - STD TI - Dyer A, Ying D, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, Jager D. Oncolytic group B adenovirus enadenotucirev mediates non-apoptotic cell death with membrane permeabilisation and release of inflammatory mediators. Mol Ther Oncolytics. 2017. ID - ref13 ER - TY - JOUR AU - Marino, N. AU - Illingworth, S. AU - Kodialbail, P. AU - Patel, A. AU - Calderon, H. AU - Lear, R. AU - Fisher, K. D. AU - Champion, B. R. AU - Brown, A. C. N. PY - 2017 DA - 2017// TI - Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes JO - PLoS One VL - 12 UR - https://doi.org/10.1371/journal.pone.0177810 DO - 10.1371/journal.pone.0177810 ID - Marino2017 ER - TY - JOUR AU - Garcia-Carbonero, R. AU - Salazar, R. AU - Duran, I. AU - Osman-Garcia, I. AU - Paz-Ares, L. AU - Bozada, J. M. AU - Boni, V. AU - Blanc, C. AU - Seymour, L. AU - Beadle, J. PY - 2017 DA - 2017// TI - Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection JO - J Immunother Cancer VL - 5 UR - https://doi.org/10.1186/s40425-017-0277-7 DO - 10.1186/s40425-017-0277-7 ID - Garcia-Carbonero2017 ER - TY - JOUR AU - Di, Y. AU - Seymour, L. AU - Fisher, K. PY - 2014 DA - 2014// TI - Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood JO - Gene Ther VL - 21 UR - https://doi.org/10.1038/gt.2014.2 DO - 10.1038/gt.2014.2 ID - Di2014 ER - TY - JOUR AU - Illingworth, S. AU - Di, Y. AU - Bauzon, M. AU - Lei, J. AU - Duffy, M. R. AU - Alvis, S. AU - Champion, B. AU - Lieber, A. AU - Hermiston, T. AU - Seymour, L. W. PY - 2017 DA - 2017// TI - Preclinical safety studies of enadenotucirev, a chimeric group B human-specific oncolytic adenovirus JO - Mol Ther Oncolytics VL - 5 UR - https://doi.org/10.1016/j.omto.2017.03.003 DO - 10.1016/j.omto.2017.03.003 ID - Illingworth2017 ER - TY - JOUR AU - Vogels, R. AU - Zuijdgeest, D. AU - Rijnsoever, R. AU - Hartkoorn, E. AU - Damen, I. AU - Bethune, M. P. AU - Kostense, S. AU - Penders, G. AU - Helmus, N. AU - Koudstaal, W. PY - 2003 DA - 2003// TI - Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity JO - J Virol VL - 77 UR - https://doi.org/10.1128/JVI.77.15.8263-8271.2003 DO - 10.1128/JVI.77.15.8263-8271.2003 ID - Vogels2003 ER - TY - JOUR AU - Holterman, L. AU - Vogels, R. AU - Vlugt, R. AU - Sieuwerts, M. AU - Grimbergen, J. AU - Kaspers, J. AU - Geelen, E. AU - Helm, E. AU - Lemckert, A. AU - Gillissen, G. PY - 2004 DA - 2004// TI - Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5 JO - J Virol VL - 78 UR - https://doi.org/10.1128/JVI.78.23.13207-13215.2004 DO - 10.1128/JVI.78.23.13207-13215.2004 ID - Holterman2004 ER - TY - JOUR AU - Small, E. J. AU - Carducci, M. A. AU - Burke, J. M. AU - Rodriguez, R. AU - Fong, L. AU - Ummersen, L. AU - Yu, D. C. AU - Aimi, J. AU - Ando, D. AU - Working, P. PY - 2006 DA - 2006// TI - A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer JO - Mol Ther VL - 14 UR - https://doi.org/10.1016/j.ymthe.2006.02.011 DO - 10.1016/j.ymthe.2006.02.011 ID - Small2006 ER - TY - JOUR AU - Tedcastle, A. AU - Illingworth, S. AU - Brown, A. AU - Seymour, L. W. AU - Fisher, K. D. PY - 2016 DA - 2016// TI - Actin-resistant DNAse I expression from oncolytic adenovirus enadenotucirev enhances its intratumoral spread and reduces tumor growth JO - Mol Ther VL - 24 UR - https://doi.org/10.1038/mt.2015.233 DO - 10.1038/mt.2015.233 ID - Tedcastle2016 ER - TY - JOUR AU - Freedman, J. D. AU - Hagel, J. AU - Scott, E. M. AU - Psallidas, I. AU - Gupta, A. AU - Spiers, L. AU - Miller, P. AU - Kanellakis, N. AU - Ashfield, R. AU - Fisher, K. D. PY - 2017 DA - 2017// TI - Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies JO - EMBO Mol Med VL - 9 UR - https://doi.org/10.15252/emmm.201707567 DO - 10.15252/emmm.201707567 ID - Freedman2017 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Ribas, A. AU - Dummer, R. AU - Puzanov, I. AU - VanderWalde, A. AU - Andtbacka, R. H. I. AU - Michielin, O. AU - Olszanski, A. J. AU - Malvehy, J. AU - Cebon, J. AU - Fernandez, E. PY - 2017 DA - 2017// TI - Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy JO - Cell VL - 170 UR - https://doi.org/10.1016/j.cell.2017.08.027 DO - 10.1016/j.cell.2017.08.027 ID - Ribas2017 ER - TY - STD TI - Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127–37. ID - ref25 ER - TY - JOUR AU - Blank, C. AU - Gajewski, T. F. AU - Mackensen, A. PY - 2005 DA - 2005// TI - Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy JO - Cancer Immunol Immunother VL - 54 UR - https://doi.org/10.1007/s00262-004-0593-x DO - 10.1007/s00262-004-0593-x ID - Blank2005 ER - TY - STD TI - Phase I study of enadenotucirev and PD-1 inhibitor in subjects with metastatic or advanced epithelial tumors (SPICE). https://clinicaltrials.gov/ct2/show/NCT02636036. Accessed 13 Nov 2017. UR - https://clinicaltrials.gov/ct2/show/NCT02636036 ID - ref27 ER - TY - JOUR AU - Ingemarsdotter, C. K. AU - Baird, S. K. AU - Connell, C. M. AU - Oberg, D. AU - Hallden, G. AU - McNeish, I. A. PY - 2010 DA - 2010// TI - Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer JO - Oncogene VL - 29 UR - https://doi.org/10.1038/onc.2010.335 DO - 10.1038/onc.2010.335 ID - Ingemarsdotter2010 ER - TY - STD TI - Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients (OCTAVE). https://clinicaltrials.gov/ct2/show/NCT02028117. Accessed 13 Nov 2017. UR - https://clinicaltrials.gov/ct2/show/NCT02028117 ID - ref29 ER -